Protagonist Therapeutics
PTGX
130 hedge funds and large institutions have $422M invested in Protagonist Therapeutics in 2022 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 44 increasing their positions, 38 reducing their positions, and 35 closing their positions.
278% more call options, than puts
Call options by funds: $18.8M | Put options by funds: $4.96M
16% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 38
5.03% more ownership
Funds ownership: 104.59% → 109.63% (+5%)
7% less funds holding
Funds holding: 140 → 130 (-10)
23% less first-time investments, than exits
New positions opened: 27 | Existing positions closed: 35
64% less capital invested
Capital invested by funds: $1.19B → $422M (-$765M)
75% less funds holding in top 10
Funds holding in top 10: 4 → 1 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$42.6M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$31M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
+$27.3M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$13.8M |
| 5 |
FC
Finepoint Capital
Boston,
Massachusetts
|
+$8.89M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$44M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
-$37.2M |
| 3 |
AG
Artal Group
Luxembourg
|
-$18.9M |
| 4 |
FFM
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$13M |
| 5 |
OWP
Obermeyer Wealth Partners
Aspen,
Colorado
|
-$9.51M |
PTGX Hedge Fund Activity: Q2 2022 in Review
130 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q2 2022, worth a combined $422M — down 64% from $1.19B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of PTGX and 27 opened new positions — a net loss of 8 holders — while 38 trimmed existing stakes and 44 added.
The largest buyer was State Street, adding an estimated $42.6M. The largest seller was Fidelity Investments, cutting an estimated $44M.
- 130 institutional investors held Protagonist Therapeutics (PTGX) as of Q2 2022, down from 140 in Q1 2022.
- Funds reported $422M of Protagonist Therapeutics stock for Q2 2022, down 64% quarter-over-quarter.
- 27 funds opened new Protagonist Therapeutics positions in Q2 2022 and 35 closed out, a net change of -8 holders.
- The largest Protagonist Therapeutics buyer in Q2 2022 was State Street, an estimated $42.6M added.
- The largest Protagonist Therapeutics seller in Q2 2022 was Fidelity Investments, an estimated $44M sold.
Based on aggregated 13F filings for Q2 2022.